Targets of acinetobacter baumannii

Inventors

Urwyler, Simon • Haake, Markus • Rudolf, Michael

Assignees

Aridis Pharmaceuticals Inc

Abstract

The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.

Core Innovation

The invention provides antigenic, immunostimulatory polypeptides from Acinetobacter baumannii and compositions that generate an immune response in a subject in need thereof. The antigenic polypeptides include isolated recombinant antigenic polypeptides defined by specific sequences, including polypeptides encoded by recombinant nucleic acid molecules consisting of the polynucleotide sequence of SEQ ID NO: 11 and polypeptides having the amino acid sequence of SEQ ID NO: 12.

The invention further includes isolated recombinant polypeptides defined by an amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO: 11 and comprising a His tag, as well as isolated recombinant polypeptides consisting of the sequence of SEQ ID NO: 12 and a His tag. The immunogenic polypeptide in at least some embodiments is described as having immunostimulatory activity in combination with an immuno-effective amount of an adjuvant.

In support of antigen selection and binding, the document describes identification and characterization of antigenic polypeptides from Acinetobacter baumannii using shedome analysis, comparative proteomics, and recognition by convalescent patient sera, including conservation across clinical isolates and expression during infection. The document reports an epitope mapping result that identifies a PVDFTVAI consensus motif (SEQ ID NO:36) as a preferred mAb/fragment binding epitope, and describes antibody binding and related immunologic measurements including ELISA, immunoblotting, FACS, and immunofluorescence.

Claims Coverage

The partial claim set contains four independent claims that collectively cover immunogenic compositions with defined recombinant Acinetobacter baumannii antigenic polypeptides, an immuno-effective amount of an adjuvant, and recombinant polypeptides with a His tag. The core inventive content centers on SEQ ID NO:11 and SEQ ID NO:12, their combination with an adjuvant, and the optional presence of a His tag.

Taken together, the independent claims cover immunogenic compositions using defined recombinant Acinetobacter baumannii antigenic polypeptides specified by SEQ ID NO: 11 and/or SEQ ID NO: 12, combined with an immuno-effective adjuvant amount, and recombinant polypeptides that include a His tag.

Stated Advantages

Documented Applications

No documented applications found